Redcare Pharmacy's Prescription for Growth Faces a Costly Reality Check

Redcare Pharmacy's Q1 2026 revenue beat expectations, driven by 35% growth in prescription drugs. Despite the strong start, shares remain down 43% YTD due to heavy investment costs.

A single-day surge of over 14% for Redcare Pharmacy stock signals a market pleasantly surprised. The German online pharmacy's preliminary first-quarter figures for 2026 handily beat expectations, yet the celebratory mood is tempered by a stark year-to-date performance that underscores deeper investor concerns.

The core driver of the quarterly beat was unmistakable: prescription drugs. Group-wide revenue from this Rx segment jumped 35% to 315 million euros. The German home market was particularly robust, where prescription sales soared 55% to 168 million euros, significantly outpacing the analyst consensus estimate of 162 million euros. Overall, preliminary group revenue climbed 18.3% to 848 million euros, exceeding forecasts of 837 million euros.

Beyond prescriptions, the over-the-counter business showed renewed vigor. Growth in this segment accelerated to 9.7%, a notable improvement from the 5.4% pace seen in the previous quarter. The company's customer base also expanded, reaching 14.2 million active users, up from 13.1 million a year earlier. Supporting this operational strength, the Net Promoter Score for its digital prescription service improved to 76 from 73, indicating higher user satisfaction.

In response to the strong start, analysts at Jefferies reaffirmed their Buy rating on the stock, maintaining a price target of 150 euros.

Despite the powerful quarterly figures, Redcare's shares remain under significant pressure in the broader context. Even after the recent pop, the stock is still down approximately 43% since the start of the year, ranking it among the weakest performers in Germany's MDAX index. It currently trades around 38.70 euros.

The divergence between strong sales and a weak stock price points directly to the company's costly expansion phase. Management confirmed that 2026 represents the peak of a heavy investment cycle. Capital is being poured into logistics infrastructure, most notably a new distribution center in Plzen, Czech Republic, which will add annual capacity for 15 million parcels. These substantial expenditures are pressuring margins and clouding near-term profit prospects.

The confirmed full-year outlook reflects this balancing act. Redcare targets group revenue growth of 13% to 15% for 2026, with German prescription revenue expected to exceed 670 million euros. On profitability, the company aims for an adjusted EBITDA margin of at least 2.5%.

Investors are now looking ahead to two key dates for further clarity. The Annual General Meeting on April 15 will see the official appointment of Hendrik Krampe as the new Chief Financial Officer. His extensive experience from Amazon in scaling online marketplaces is anticipated to be a key asset. The complete financial report for the first quarter, offering detailed profitability metrics, will follow on May 6.